Education
About Us
Working with TipRanks
Follow Us
UCB SA (GB:0NZT)
LSE:0NZT
0NZT Stock Chart & Stats
Day’s Range― - ―
52-Week Range€117.90 - €198.70
Previous CloseN/A
Volume490.91K
Average Volume (3M)76.59K
Market Cap
€26.31B
Enterprise Value€29.66B
Total Cash (Recent Filing)€861.00M
Total Debt (Recent Filing)€3.04B
Price to Earnings (P/E)24.4
Beta0.85
Next Earnings
Jul 24, 2025EPS Estimate
3.75Next Dividend Ex-Date
Apr 25, 2025Dividend Yield0.69%
Share Statistics
EPS (TTM)5.61
Shares Outstanding194,505,660
10 Day Avg. Volume59,833
30 Day Avg. Volume76,587
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)N/A
Price to Sales (P/S)3.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€217.43Price Target Upside54.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialThere is a scarcity value for UCB, given very few companies with clear visibility into the value drivers for the next few years, with accelerating and durable earnings potential.
Market PerformanceBimzelx H2 sales reached €393MM, with US contribution significantly above consensus, indicating strong market performance.
Product LaunchThe Bimzelx launch continues to outperform, driven by strong patient adoption in multiple conditions and improved formulary positioning.
Bears Say
Market CompetitionThere is significant unmet need for additional therapeutic options in the growing HS market, supporting Bimzelx's potential success.
Regulatory ApprovalAnalysts are optimistic about Bimzelx's anticipated FDA approval for hidradenitis suppurativa.
Sales ExpectationsUCB is expected to meet or modestly beat Street's expectations for Bimzelx sales, reflecting strong demand and improved patient access.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.70%
Mutual Funds
<0.01% Other Institutional Investors
76.88% Public Companies and
Individual Investors
0NZT FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest share price was €117.90 and its highest was €198.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is €26.31B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 24, 2025 which is in 98 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 27, 2025. The company reported €2.86 earnings per share for the quarter, beating the consensus estimate of €2.587 by €0.273.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of €0.952 which represents an annual dividend yield of 0.69%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.75.
How many shares outstanding does UCB SA have?
UCB SA has 194,505,660 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of €2.86 in its last earnings report, beating expectations of €2.587. Following the earnings report the stock price went down -1.178%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in GB:0NZT
---
Company Description
UCB SA
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Evenity (osteoporosis), and Nayzilam (cluster seizures).
---
0NZT Stock 12 Month Forecast
Average Price Target
€217.43
▲(54.40% Upside)
Technical Analysis
Best Analysts Covering 0NZT
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+19.86%
initiated a buy rating yesterday
Copying Peter Verdult's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +19.86% per trade.
---